Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 4/20 | 0.58 |
| ▸ | RAB9A | P51151 | 11/20 | 0.57 |
| ▸ | NPC1 | O15118 | 10/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.57 |
| ▸ | LMNA | P02545 | 4/20 | 0.57 |
| ▸ | HPGD | P15428 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL164034 | 0.90 | NPC1 (0.59) | TP53RAB9ANPC1SMN1; SMN2LMNA | |
| SCHEMBL161857 | 0.86 | RAB9A (0.49) | TP53RAB9ANPC1SMN1; SMN2LMNA | |
| SCHEMBL828143 | 0.83 | POLB (0.61) | TP53RAB9ANPC1SMN1; SMN2LMNA | |
| SCHEMBL159824 | 0.78 | RAB9A (0.64) | RAB9ANPC1SMN1; SMN2LMNAHPGD | |
| SCHEMBL162398 | 0.76 | MAPT (0.43) | TP53RAB9ANPC1SMN1; SMN2LMNA | |
| SCHEMBL12349834 | 0.75 | TP53 (0.78) | TP53RAB9ANPC1SMN1; SMN2LMNA | |
| SCHEMBL164699 | 0.73 | RAB9A (0.58) | TP53RAB9ANPC1SMN1; SMN2HPGD | |
| SCHEMBL6360480 | 0.73 | ALDH1A1 (0.72) | TP53RAB9ANPC1SMN1; SMN2LMNA | |
| SCHEMBL17117168 | 0.73 | NPC1 (1.00) | TP53RAB9ANPC1SMN1; SMN2LMNA | |
| SCHEMBL19064377 | 0.72 | RAB9A (0.54) | TP53RAB9ANPC1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9856210-B2 | Pharmaceutical composition for prevention and treatment of amyotrophic lateral sclerosis | KYOTO UNIVERSITY (JP) | 2018-01-02 | — | — | US | disclosed |
| EP-2611437-B1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | UNIV KYOTO (JP) | 2017-03-29 | — | — | EP | disclosed |
| US-20130225642-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | KYOTO UNIVERSITY (JP) | 2013-08-29 | — | — | US | disclosed |
| EP-2611437-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | Kyoto University (JP) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012029994-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | KYOTO UNIVERSITY (JP) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225642-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | SMN1; SMN2, SOD1, SOD3 | TP53 2226/4885RAB9A 3460/4885NPC1 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.